20/20 Biolabs, Inc. Common Stock (AIDX) Stock Price
AIDXStock
$0.26
Market Cap$3.33M
P/E—
PEG Ratio—
Div yield—
Beta2.42
AIDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-94.75%
Price vs S&P 500 (4W)-43.22%
VGM Score8.44
AIDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.12 | -$0.26 | -116.67%(-$0.14) | |
| Q1 2026 | -$0.10 | -$0.28 | -180.00%(-$0.18) |
AIDX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14
Industry Peers — Testing Laboratories(3)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
AIDX20/20 Biolabs, Inc. Common Stock | — | — | F | — | — | — | — | $0.26 |
| ULSUL Solutions Inc. | D | B | C | 45.5x | 37.6% | — | 0.7% | $73.31 |
| NEONeoGenomics, Inc. | D | C | A | — | -6.3% | 10.3% | — | $16.65 |
| BNBXBNB Plus Corp. Common Stock | — | D | D | — | -337.1% | 2.0% | — | $0.10 |
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs is a commercial-stage diagnostics company developing ML-powered laboratory tests for early disease detection. The company offers two main products: OneTest for Cancer, a multi-cancer early detection blood test, and OneTest for Longevity, which measures inflammatory biomarkers. Both tests leverage real-world data to enhance diagnostic accuracy and clinical utility.